Juergen Rockstroh

5.4k total citations
47 papers, 2.0k citations indexed

About

Juergen Rockstroh is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Juergen Rockstroh has authored 47 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 31 papers in Hepatology and 19 papers in Infectious Diseases. Recurrent topics in Juergen Rockstroh's work include Hepatitis C virus research (31 papers), Hepatitis B Virus Studies (20 papers) and Liver Disease Diagnosis and Treatment (19 papers). Juergen Rockstroh is often cited by papers focused on Hepatitis C virus research (31 papers), Hepatitis B Virus Studies (20 papers) and Liver Disease Diagnosis and Treatment (19 papers). Juergen Rockstroh collaborates with scholars based in Germany, United States and United Kingdom. Juergen Rockstroh's co-authors include Vincent Soriano, Massimo Puoti, Yves Benhamou, Stefan Mauss, Karine Lacombe, Marion G. Peters, Mark Sulkowski, Antonietta Cargnel, Pablo Barreiro and Angelos Hatzakis and has published in prestigious journals such as PLoS ONE, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Juergen Rockstroh

46 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juergen Rockstroh Germany 26 1.2k 1.2k 712 486 264 47 2.0k
J. J. Goedert United States 20 1.1k 0.9× 842 0.7× 802 1.1× 534 1.1× 219 0.8× 34 2.0k
Shahin Gharakhanian France 14 1.0k 0.9× 1.0k 0.9× 697 1.0× 401 0.8× 93 0.4× 29 1.9k
JK Rockstroh Germany 19 775 0.7× 417 0.4× 782 1.1× 420 0.9× 489 1.9× 63 1.9k
Raffaele Malinverni Switzerland 22 1.0k 0.9× 549 0.5× 648 0.9× 288 0.6× 153 0.6× 36 1.7k
Eugenia Vispo Spain 31 1.8k 1.5× 1.9k 1.6× 1.1k 1.6× 489 1.0× 122 0.5× 104 2.9k
Barbara McGovern United States 5 831 0.7× 1.0k 0.9× 385 0.5× 186 0.4× 273 1.0× 7 1.4k
A Sánchez-Quijano Spain 18 1.1k 1.0× 984 0.9× 531 0.7× 337 0.7× 169 0.6× 52 1.7k
Gabriella Verucchi Italy 21 1.5k 1.3× 1.5k 1.3× 286 0.4× 173 0.4× 101 0.4× 86 2.0k
Caroline Lascoux‐Combe France 22 944 0.8× 764 0.7× 448 0.6× 297 0.6× 100 0.4× 64 1.5k
Javier García‐Samaniego Spain 34 3.3k 2.9× 3.5k 3.0× 1.2k 1.6× 279 0.6× 179 0.7× 163 4.3k

Countries citing papers authored by Juergen Rockstroh

Since Specialization
Citations

This map shows the geographic impact of Juergen Rockstroh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Rockstroh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Rockstroh more than expected).

Fields of papers citing papers by Juergen Rockstroh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen Rockstroh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Rockstroh. The network helps show where Juergen Rockstroh may publish in the future.

Co-authorship network of co-authors of Juergen Rockstroh

This figure shows the co-authorship network connecting the top 25 collaborators of Juergen Rockstroh. A scholar is included among the top collaborators of Juergen Rockstroh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juergen Rockstroh. Juergen Rockstroh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martinello, Marianne, Susanna Naggie, Juergen Rockstroh, & Gail Matthews. (2023). Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review. Clinical Infectious Diseases. 77(Supplement_3). S238–S244. 27 indexed citations
2.
Wohl, David A., et al.. (2022). COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines. ERJ Open Research. 8(4). 236–2022. 2 indexed citations
3.
Dharan, Nila J., Jacqueline Neuhaus, Juergen Rockstroh, et al.. (2018). Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology. 69(3). 1135–1150. 11 indexed citations
4.
Grint, Daniel, Lars Peters, Juergen Rockstroh, et al.. (2015). Liver-related death among HIV/hepatitis C virus-co-infected individuals. AIDS. 29(10). 1205–1215. 25 indexed citations
5.
Neukam, Karin, Daniela Munteanu, Antonio Rivero‐Juárez, et al.. (2015). Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PLoS ONE. 10(4). e0125080–e0125080. 9 indexed citations
6.
Squires, Kathleen, Linda‐Gail Bekker, Joseph J. Eron, et al.. (2013). Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study. AIDS Research and Human Retroviruses. 29(6). 859–870. 16 indexed citations
7.
Lawitz, Eric, Mark Sulkowski, Ira M. Jacobson, et al.. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research. 99(3). 214–220. 26 indexed citations
8.
Vispo, Eugenia, Müge Çevik, Juergen Rockstroh, et al.. (2013). Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. Clinical Infectious Diseases. 56(8). 1117–1122. 21 indexed citations
9.
Krämer, Benjamin, Hans Dieter Nischalke, Christoph Boesecke, et al.. (2013). Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS. 27(17). 2817–2819. 14 indexed citations
10.
Lacombe, Karine & Juergen Rockstroh. (2012). HIV and viral hepatitis coinfections: advances and challenges. Gut. 61(Suppl 1). i47–i58. 104 indexed citations
11.
Lankisch, Tim O., Georg M. N. Behrens, Ursula Ehmer, et al.. (2009). Gilbert’s syndrome and hyperbilirubinemia in protease inhibitor therapy – An extended haplotype of genetic variants increases risk in indinavir treatment. Journal of Hepatology. 50(5). 1010–1018. 30 indexed citations
12.
Sankatsing, Raaj R., Ferdinand W.N.M. Wit, Martin Vogel, et al.. (2008). Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis. 202(2). 589–595. 43 indexed citations
13.
Kuntzen, Thomas, Cristina Tural, Bin Li, et al.. (2008). Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS. 22(2). 203–210. 27 indexed citations
14.
Soriano, Vincent, Massimo Puoti, Mark Sulkowski, et al.. (2007). Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS. 21(9). 1073–1089. 256 indexed citations
15.
Nattermann, Jacob, Martin Vogel, Thomas Berg, et al.. (2007). Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology. 46(4). 1016–1025. 35 indexed citations
16.
Schmutz, Guenther, Mark Nelson, Thomas A. Lutz, et al.. (2006). Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 20(15). 1951–1954. 66 indexed citations
17.
Streeck, Hendrik, Heiko Jessen, Galit Alter, et al.. (2006). Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during Acute HIV‐1 Infection. The Journal of Infectious Diseases. 194(6). 734–739. 67 indexed citations
18.
Sheldon, Julie, Angélica Corral, Berta Rodés, et al.. (2005). Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS. 19(17). 2036–2038. 43 indexed citations
19.
Hoffmann, Christian, Kai Uwe Chow, Eva Wolf, et al.. (2004). Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus‐associated Hodgkin's disease. British Journal of Haematology. 125(4). 455–462. 66 indexed citations
20.
Kreuzer, Karl‐Anton, Juergen Rockstroh, Tilman Sauerbruch, & Ulrich Spengler. (1996). A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-α. Journal of Immunological Methods. 195(1-2). 49–54. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. J. Goedert Breakdown of academic impact, for papers by Shahin Gharakhanian Breakdown of academic impact, for papers by JK Rockstroh Breakdown of academic impact, for papers by Raffaele Malinverni Breakdown of academic impact, for papers by Eugenia Vispo Breakdown of academic impact, for papers by Barbara McGovern Breakdown of academic impact, for papers by A Sánchez-Quijano Breakdown of academic impact, for papers by Gabriella Verucchi Breakdown of academic impact, for papers by Caroline Lascoux‐Combe Breakdown of academic impact, for papers by Javier García‐Samaniego
Rankless by CCL
2026